SCHEMBL1160975

SCHEMBL1160975

COc1ccc(CN2Cc3c(Cl)ccnc3NC2=O)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 1/20 0.50
IDH1 O75874 1/20 0.45
ALDH1A1 P00352 4/20 0.41
MAPT P10636 2/20 0.41
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
CYP11B2 P19099 1/20 0.41
CMA1 P23946 1/20 0.40
NPBWR1 P48145 1/20 0.40
AURKA O14965 1/20 0.39
HDAC6 Q9UBN7 1/20 0.39
BLM P54132 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
MMP1 P03956 1/20 0.39
MMP13 P45452 1/20 0.39
CLPP Q16740 1/20 0.39
GSK3A P49840 1/20 0.39
GSK3B P49841 1/20 0.39
GRM2 Q14416 1/20 0.39
SMN1; SMN2 Q16637 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16340469 0.87 GAA (0.49) GAAIDH1ALDH1A1MAPTMEN1
SCHEMBL11030454 0.79 ACE (0.36) IDH1BLMMMP13CYP1A2LMNA
SCHEMBL11029036 0.79 IDH1 (0.42) GAAIDH1ALDH1A1MAPTCYP11B2
SCHEMBL11027623 0.79 GAA (0.42) GAAIDH1ALDH1A1MAPTMEN1
SCHEMBL11030775 0.77 EPHB4 (0.49) IDH1
SCHEMBL11029374 0.77 KDM4E (0.43) GAAIDH1ALDH1A1AURKAHDAC6
SCHEMBL11027622 0.77 GAA (0.40) GAAIDH1ALDH1A1HDAC6MMP1
SCHEMBL11029418 0.76 IDH1 (0.44) GAAIDH1ALDH1A1MAPTMMP13
SCHEMBL11030059 0.76 GAA (0.39) GAAIDH1ALDH1A1MAPTAURKA
SCHEMBL11039120 0.76 MAPK10 (0.47) GAAIDH1MEN1KMT2AHDAC6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2742043-B1 PYRIDO-PYRIMIDINE DERIVATIVES MERCK PATENT GMBH (DE) 2016-10-26 EP disclosed
US-9283225-B2 Pyrido-pyrimidine derivatives MERCK PATENT GMBH (DE) 2016-03-15 US disclosed
US-20140228379-A1 Pyrido-Pyrimidine Derivatives MERCK PATENT GMBH (DE) 2014-08-14 US disclosed
US-20140228379-A1 Pyrido-Pyrimidine Derivatives MERCK PATENT GMBH (DE) 2014-08-14 US disclosed
US-8569295-B2 Bicyclic urea compounds MERCK PATENT GMBH (DE) 2013-10-29 US disclosed
US-8569295-B2 Bicyclic urea compounds MERCK PATENT GMBH (DE) 2013-10-29 US disclosed
US-8569295-B2 Bicyclic urea compounds MERCK PATENT GMBH (DE) 2013-10-29 US disclosed
EP-2461869-B1 NOVEL BICYCLIC UREA COMPOUNDS MERCK PATENT GMBH (DE) 2013-08-21 EP disclosed
WO-2013022519-A1 PYRIDO-PYRIMIDINE DERIVATIVES MERCK PATENT GMBH (DE) 2013-02-14 WO disclosed
US-20120190654-A1 NOVEL BICYCLIC UREA COMPOUNDS MERCK PATENT GMBH (DE) 2012-07-26 US disclosed
US-20120190654-A1 NOVEL BICYCLIC UREA COMPOUNDS MERCK PATENT GMBH (DE) 2012-07-26 US disclosed
US-20120190654-A1 NOVEL BICYCLIC UREA COMPOUNDS MERCK PATENT GMBH (DE) 2012-07-26 US disclosed
EP-2461869-A1 NOVEL BICYCLIC UREA COMPOUNDS Merck Patent GmbH (DE) 2012-06-13 EP disclosed
WO-2011017142-A1 NOVEL BICYCLIC UREA COMPOUNDS MERCK PATENT GMBH (DE) 2011-02-10 WO disclosed
WO-2011017142-A1 NOVEL BICYCLIC UREA COMPOUNDS MERCK PATENT GMBH (DE) 2011-02-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120190654-A1 NOVEL BICYCLIC UREA COMPOUNDS CCNC, CCNI, CCNA1 GAA 3502/4885IDH1 747/4885ALDH1A1 1372/4885
US-20140228379-A1 Pyrido-Pyrimidine Derivatives DPYD, CDK2, CDK1 GAA 4465/4885IDH1 87/4885ALDH1A1 1306/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.